Correction to “Tumor‐Activatable Nanoparticles Target Low‐Density Lipoprotein Receptor to Enhance Drug Delivery and Antitumor Efficacy”

Documenti analoghi

• Anti‐HER2 Immunoliposomes: Antitumor Efficacy Attributable to Targeted Delivery of Anthraquinone‐Fused Enediyne
  di: Xueqiong Feng, et al.
  Pubblicazione: (2024)
• Ferritin‐Based Supramolecular Assembly Drug Delivery System for Aminated Fullerene Derivatives to Enhance Tumor‐Targeted Therapy
  di: Baoli Zhang, et al.
  Pubblicazione: (2024)
• Nanoparticle Drug Delivery Systems for Atherosclerosis: Precision Targeting, Inflammatory Modulation, and Plaque Stabilization
  di: Yunqi Zhang, et al.
  Pubblicazione: (2025)
• Neurophilic Biomimetic Lipoprotein‐Mediated Targeted Nerve Growth Factor Delivery for Traumatic Brain Injury Therapy
  di: Jialin Huang, et al.
  Pubblicazione: (2025)
• On‐Demand Controlled Release Multi‐Drugs Delivery System for Spatiotemporally Synergizing Antitumor Immunotherapy
  di: Chenglin Liang, et al.
  Pubblicazione: (2025)